Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

UBS Analyst Karl Keirstead Maintains Neutral Rating on Xometry with Lowered Price Target

Elaine Mendonca by Elaine Mendonca
March 13, 2024
in Breaking News
0
DVY stock news
0
SHARES
7
VIEWS
Share on FacebookShare on Twitter

UBS analyst Karl Keirstead is keeping a Neutral rating on Xometry (NASDAQ: XMTR) as of March 13, 2024. He has revised the price target down to $21 from $22, citing a softer revenue forecast for the company.

Keirstead, known for his accuracy in stock analysis, covers 29 stocks with a success rate of 65.71% and an average return of 18.8%.

XMTR Stock Plummets on March 13, 2024, Trading Near 52-Week Low

On March 13, 2024, XMTR stock experienced a decline in its performance, trading near the bottom of its 52-week range and below its 200-day simple moving average. The stock opened at $17.91, which was $0.16 lower than its previous close. Throughout the trading day, the price of XMTR shares continued to drop, decreasing by $0.50 or 2.77% since the market last closed.

XMTR Stock Analysis: Promising Revenue Growth and Improved EPS on March 13, 2024

On March 13, 2024, XMTR stock showed promising performance based on the financial data provided by CNN Money. The company reported a total revenue of $463.41 million for the past year, showing a 21.61% increase compared to the previous year. In the fourth quarter, XMTR generated $128.15 million in total revenue, which represents a 7.75% increase from the previous quarter.

Despite the positive revenue growth, XMTR reported a net income of -$67.47 million for the year, with a smaller net loss of -$10.55 million in the fourth quarter. The net income increased by 11.25% compared to the previous year, but remained stable from the previous quarter. Earnings per share (EPS) also improved, with a reported EPS of -$1.41 for the year and -$0.22 for the fourth quarter. The EPS increased by 12.65% since last year and by 12.42% since the previous quarter.

Overall, XMTR stock showed resilience and growth in its financial performance on March 13, 2024. The increase in total revenue and EPS indicates that the company is on the right track towards profitability. Investors may view these positive financial indicators as a sign of potential future growth and may consider investing in XMTR stock. However, it is important to conduct further research and analysis before making any investment decisions.

Tags: XMTR
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Cryptocurrency Stock Market Today

Navigating Uncertainties The Death Cross in Crypto Mining Stocks

Investings on laptops and finances

Analyzing GoHealths Earnings and Stock Performance

Renewable energy

Montauk Renewables Earnings Preview and Stock Analysis

Recommended

Torrid Holdings Stock

Torrid Holdings Faces Critical Earnings Test

5 months ago
Take-Two Stock

Take-Two Shares in Holding Pattern as Investors Await GTA VI Details

6 months ago
Union Pacific Stock

Union Pacific’s Future Hangs in Balance as Historic Railroad Merger Faces Critical Vote

4 months ago
Biotechnology Markets and money

BioTechnes Quarterly Earnings and Stock Performance Analysis

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Blue Ridge Bankshares Emerges from Regulatory Challenges with Return to Profitability

Navigating the Interest Rate Tightrope: Bank7’s Path Forward

Claros Mortgage Trust Secures Financial Flexibility Through Strategic Debt Overhaul

Trending

Vigil Neuroscience Stock
Healthcare

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

by SiterGedge
February 7, 2026
0

The integration of Vigil Neuroscience into French pharmaceutical giant Sanofi has been finalized. This strategic move, which...

Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

February 7, 2026
Graftech Stock

Graftech Shares Plunge on Bleak Quarterly Results

February 7, 2026
Potbelly Stock

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy
  • Repay Holdings: Annual Report to Test Strategic Refinancing Success
  • Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com